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he number of dementia victims keeps increasing
at a fast rate, reaching pandemic proportions. Because of
increased life expectancy, the number of people affected
with dementia will double every 20 years and exceed 80
million by the year 2040. Even now the majority of peo-
ple with dementia live in developing countries, and this
proportion is expected to increase in the future. By the
year 2040, the number of individuals with dementia in
Asian countries (particularly India and China) will
increase by more than 200%.
1The victims are not just the
patients themselves; the whole family is always affected.
Moreover, there is a huge economic impact on society
which will only become larger. A handful of drugs have
been developed for the treatment of dementia and par-
ticularly Alzheimer’s disease (AD). These drugs are
approved for this condition, but unfortunately they have
only a small effect, and none can offer a cure. Although
better solutions will surely be discovered, none seems to
become available in the visible future. Moreover, once
developed, these therapies are likely to be costly.
The key to the development of new drugs is understand-
ing the mechanism of the disease, or at least identifying
(and controlling) the risk factors. Indeed, several impor-
tant leads have been identified which justify optimism. In
this paper, I discuss the recently identified risk factors for
dementia, and suggest how preventative measures can
delay the onset of dementia. Obviously, it is always bet-
ter to prevent a disease from occurring altogether.
Dementia is not a disease, but rather a syndrome that
encompasses dozens of clinical entities caused by neu-
rodegeneration, trauma, strokes, immunological
processes, or infections. The two most common forms of
dementia are considered to be AD and vascular demen-
tia (VaD). Conceptually, these are completely different
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Dementia is an important public health problem of
increasing magnitude. At present, available therapies
provide only minor and temporary relief, and attempts
to find a cure have so far failed. Epidemiological studies
have identified risk factors for dementia, particularly
Alzheimer's disease and vascular dementia.
In principle, these findings provide an opportunity to
intervene and prevent the dementia epidemic. Attention
to nongenetic risk factors such as hypertension, hyper-
lipidemia, smoking, and obesity may thus not only pre-
vent cardiovascular disease but also dementia, although
it is difficult to prove the efficacy of these measures for
dementia prevention.
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the brain through ischemic strokes or hemorrhages.
However, the distinction between the two entities is
blurred. The phenomenology of AD and of VaD are
largely overlapping and in older people it is unusual not
to find a combination of Alzheimer and vascular pathol-
ogy at autopsy.
2-4 Although one factor or another may
dominate the clinical and pathological picture in individ-
ual cases, it would be mistaken to disregard the other. A
clear example of an interaction between neurodegener-
ation and vascular brain disease is the important Nun
Study.
5 Nuns in whom autopsy established a diagnosis of
AD had not always been demented clinically. The main
difference between women with AD changes who had
been demented and those who had not, was not the
extent and severity of the Alzheimer pathology, but
rather the coexistence of discrete vascular changes, such
as basal ganglia lacunar infarcts. These “minor” ischemic
changes were sufficient to tip the balance and to make
the AD changes manifest clinically as dementia.
Many risk factors for dementia have been identified in
recent years, most of which are common, and several are
associated with both AD and VaD, as well as with ather-
osclerosis.
6,7These include age, hypertension, diabetes mel-
litus, dyslipidemia, hyperhomocysteinemia, obesity, smok-
ing, coronary artery disease, and low level of education
and occupational attainment.
8-11 It is important to note that
many of these risk factors seem to exert their critical
effects already in midlife.
12 In senescence, the changes may
have disappeared. Most elderly are not overweight any
more, have stopped smoking (if they ever did), and even
their cholesterol levels are lower than they have ever been.
It is important to realize that an interaction exists
between these factors. For example, highly educated peo-
ple are more likely to follow a healthy lifestyle, eat a
healthy diet, not smoke, be involved in stimulating intel-
lectual activities, promote their physical health through
more strict attention to hypertension and hypercholes-
terolemia, etc. This makes it almost impossible to sepa-
rate individual components potentially contributing to or
slowing intellectual decline in old age.
Since many risk factors are common to AD and VaD, the
distinction between these two “entities” is not so impor-
tant from an interventionalist point of view, and attention
to the risk factors mentioned above could be effective in
controlling various forms of cognitive impairment.
Prevention of dementia is theoretically possible if the risk
factors are identified and successfully treated in time.
While early intervention is desirable, it should be recalled
that by the time a person develops the first clinical mani-
festation of AD, brain pathology is already widespread.
4,13
According to accepted estimates, the preclinical stage of
AD may be as long as 10 years. Most of the prospective
studies that were done, or are being performed at present,
in attempt to reduce the incidence of dementia thus actu-
ally refer to secondary prevention, ie, assess the appear-
ance of symptoms rather than of the first neuropatholog-
ical changes, even if this is not usually acknowledged.
The overlap between AD and VaD probably means that
there will never be a single mechanism by which this ter-
rible disease can be prevented. However, attention to risk
factors is likely to reduce the incidence of dementia.
The best supportive data on the importance of these risk
factors that we have come from observations like the
CAIDE study in Finland,
12 in which the incidence of
dementia was estimated over a period of 20 years. Similar
data were derived from several expensive studies extend-
ing for decades. However, in such studies the control
group is not randomized, and in any case the results that
demonstrate an association can only suggest causation,
not prove it. It has been more difficult to accumulate
prospective data on whether treatment of these risk fac-
tors can delay the onset of dementia. For example, only
meager data exist to support the idea that treatment of
hypertension, one of the most common risk factors, is
efficacious in reducing the incidence of dementia. An
important example is the SystEur study, in which elderly
subjects with systolic hypertension were treated with
either nitrendipine or placebo. After only 2 years, the
treatment was successful in reducing end point events,
including the occurrence of dementia. Interestingly, the
reduction included cases diagnosed clinically as having
AD as well as VaD.
14 Retrospective analysis also confirms
that treatment with statins reduces the occurrence of
dementia in patients with hypercholesterolemia,
15,16 and
prospective data support this conclusion.
17 However, it is
unknown whether the results can be extrapolated to peo-
ple with cholesterol levels in the “normal” range.
Several studies in different populations have suggested
that late-life depression is another important risk factor
for dementia. The underlying mechanisms are complex
and still unclear, but the existence of cerebral white mat-
ter damage in depressed individuals
18 suggest vascular
changes as one mechanism. Therefore, depressed individ-
uals must be treated intensively and aggressively if they
have vascular disease such as hypertension, or changes
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and possibly hyperhomocysteinemia, among others. Such
therapy should continue and be monitored even after the
depression remits. Another presumed connection
between depression and dementia is hypercortisolism,
frequently found in depression. At high concentrations,
cortisol is toxic to the brain and particularly to the hip-
pocampus which has a high concentration of steroid
receptors. At present, treatment of depressed individuals
targets behavioral end points, such as affect and sleep dis-
turbances. However, it is possible that patients may have
persistent hypercortisolemia even after remission of the
clinical manifestations. If this is the case, monitoring and
normalization of cortisol levels may be important.
19
The degenerative brain disease involves a complex
inflammatory response consisting of cytokine release and
microglial activation, among others. Interestingly, several
epidemiological studies have suggested that nonsteroidal
anti-inflammatory drugs, including aspirin, may attenu-
ate the neurodegeneration and delay or prevent the
onset of dementia.
20-22These conclusions were the result
of retrospective analysis of people treated by different
drugs at various levels, for varying periods of time, so that
exact information is not available.
A popular hypothesis suggests that oxidative stress is
involved in neurodegenerative processes. While this theory
is unsubstantiated, it has not been refuted so far. Moreover,
several prospective data demonstrate an association
between consumption of dietary antioxidants and reduced
incidence of dementia. The data do not point to a single
antioxidant but rather to a diet such as the Mediterranean
diet, which is low in saturated fats and rich in fish, olive oil,
and vegetables, particularly leafy ones which contain vita-
min E. Other sources of data confirm that dietary vitamin
E, but not supplements, are key to this beneficial effect.
23
Another important source of antioxidants can be red
wine, and although several studies confirm the beneficial
effect of wine if consumed in moderation (approximately
1 glass per day), no study has demonstrated an advantage
of red wine over other alcoholic drinks.
One important caveat is the fact that all the abovemen-
tioned risk factors (Table I) act during midlife, rather
than at an advanced age. This establishes a “window of
opportunity” during which the interventions must be
used. Apparently once the pathological process is fully
active, interventions might not be effective any more.
Why is it so difficult to accumulate supporting evidence
on the protective effects of antihypertensive or choles-
terol-lowering drugs against dementia? Firstly, it is uneth-
ical to perform placebo-controlled studies on the treat-
ment of these disorders in people who are hypertensive
or hypercholesterolemic. Syst-Eur was possible only
because at the time there was no consensus as to whether
systolic hypertension per se should be treated in the
elderly. In addition, such studies are long and costly, and
thus not appealing to investigators and financing agen-
cies. Strictly speaking, the results of Syst-Eur only apply
to treatment of systolic hypertension in the elderly where
we are allowed to assume that it will result in reduced
incidence of dementia. Although it is logical to extrapo-
late these results to younger people, or those with more
severe forms of hypertension, technically an effect in
these situations has not been proven.
Obesity has also been associated with the occurrence of
dementia.
10 Of course, no randomized studies can ever be
performed to establish whether prevention (or treatment)
of obesity can reduce the incidence of dementia. Similarly,
no class I evidence will ever demonstrate whether physi-
cal or intellectual activities, wine drinking or cessation of
smoking in midlife can either singly or in combination
affect the incidence of dementia several decades later.
Nevertheless, nobody is likely to contest the idea that
overweight or smoking are bad for health in general, and
therefore attempts to reduce obesity and to stop smok-
ing are promoted by physicians even without referring to
the cognitive aspects.
It is with this view that we have to approach the other risk
factors mentioned above. It should be stressed again that
most of these risk factors predispose to the occurrence of
dementia several decades later. Low level of education and
head trauma are examples of such delayed effects, but this
is also true for hypertension, diabetes, hyperlipidemia, and
more, where it is their midlife occurrence which is associ-
ated with the development of dementia in senescence.
Not all the factors mentioned here are equally important
(and data are missing on several), and some may be
redundant to others. It is difficult to envisage that we
shall ever be able to definitely confirm that manipulation
of these risk factors can reduce the risk of dementia, and
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- Smoking
- High blood pressure
- Diabetes mellitus
- Dietary unsaturated fat
- Serum cholesterol
Table I. Midlife factors associated with development of dementia in old age.
215what is their quantitative effect singly or in different com-
binations. Nevertheless, it is more than reasonable to pro-
mote physical health in order to prevent dementia. Since
the prevalence of dementia doubles every 5 years after
age 65, delaying the onset of dementia by 10 years could
markedly reduce age-specific prevalence, particularly in
people who are still in critical productive years by 75%.
This is probably achievable.  ❏
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¿Se puede evitar la demencia?
La demencia es un importante problema de salud
pública de magnitud creciente. Actualmente, las tera-
pias disponibles proporcionan sólo un alivio menor y
temporal, y a la fecha los intentos por encontrar una
cura han fallado. Los estudios epidemiológicos han
identificado factores de riesgo para la demencia, espe-
cialmente para la Enfermedad de Alzheimer y la
demencia vascular. En principio, estos hallazgos pro-
porcionan una oportunidad para intervenir y prevenir
la demencia epidémica. El centrar la atención en fac-
tores de riesgo no genéticos como la hipertensión, la
hiperlipidemia, el tabaquismo y la obesidad puede pre-
venir no sólo la enfermedad cardiovascular sino tam-
bién la demencia, aunque es difícil probar la eficacia
de estas medidas para la prevención de esta última.
Peut-on éviter la démence ?
La démence est un important problème de santé
publique d’ampleur croissante. Les traitements actuelle-
ment disponibles n’offrent qu’un soulagement mineur et
temporaire, et les tentatives pour obtenir une guérison
ont jusqu’à présent échoué. Des études épidémiologiques
ont identifié les facteurs de risque de démence, en parti-
culier de la maladie d’Alzheimer et de la démence vascu-
laire. Ces découvertes fournissent  en principe des oppor-
tunités de stopper et de prévenir l’épidémie de démence.
L’intérêt porté aux facteurs de risque non génétiques tels
que l’hypertension, l’hyperlipidémie, le tabagisme et
l’obésité pourrait non seulement permettre d’éviter les
pathologies cardiovasculaires, mais aussi la démence, bien
qu’il soit difficile de prouver l’efficacité de ces mesures
pour sa prévention.
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